Founded in 2008, Adarza BioSystems, Inc. has developed a highly sensitive label-free diagnostic platform capable of measuring 100s more individual proteins than the best multiplex immunoassays available today.
Adarza is a leading developer and manufacturer of label-free biosensor assays and instruments servicing life science research, drug development and, in-vitro diagnostics customers.
Adarza offers a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.
Adarza’s platform is capable of rapidly identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing.
Adarza’s technology offers key performance benefits in speed, ease of use, large screening arrays, and custom assays as well as industry-standard expectations for sensitivity, sample size, and dynamic range.
Adarza products address broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology, and infectious diseases research.
Locations
Cohorts
Industries
Financials
- $64.1m
- 29